Get the Stockscreener App
95.40
3.49%
3.22
After Hours:
95.33
-0.07
-0.07%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Abbott Laboratories stock is traded at $95.40, with a volume of 10.49M.
It is up +3.49% in the last 24 hours and up +9.69% over the past month.
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives roughly 60% of sales outside the United States.
See More
Previous Close:
$92.18
Open:
$93.41
24h Volume:
10.49M
Relative Volume:
0.82
Market Cap:
$166.17B
Revenue:
$45.13B
Net Income/Loss:
$6.28B
P/E Ratio:
26.58
EPS:
3.5895
Net Cash Flow:
$7.38B
1W Performance:
+2.32%
1M Performance:
+9.69%
6M Performance:
-23.18%
1Y Performance:
-28.86%
1-Day Range:
$91.91
$95.74
1-Week Range:
$90.61
$95.74
52-Week Range:
$81.97
$137.49
Abbott Laboratories Stock (ABT) Company Profile
Name
Abbott Laboratories
Sector
Industry
Phone
(224) 667-6100
Address
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Compare ABT vs SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
95.40 | 158.05B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
326.54 | 120.70B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
83.19 | 100.14B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
45.14 | 63.44B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
94.37 | 52.09B | 6.30B | 1.07B | 1.09B | 1.8406 |
Abbott Laboratories Stock (ABT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-22-26 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Oct-10-25 | Initiated | The Benchmark Company | Buy |
| Jul-18-25 | Upgrade | Jefferies | Hold → Buy |
| Jun-16-25 | Initiated | Leerink Partners | Market Perform |
| Oct-08-24 | Initiated | Oppenheimer | Outperform |
| Sep-19-24 | Initiated | Piper Sandler | Overweight |
| Jul-30-24 | Downgrade | Edward Jones | Buy → Hold |
| May-30-24 | Initiated | Goldman | Buy |
| Jul-21-23 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| May-30-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-20-23 | Reiterated | Barclays | Overweight |
| Apr-20-23 | Reiterated | Bernstein | Outperform |
| Apr-20-23 | Reiterated | JP Morgan | Overweight |
| Apr-20-23 | Reiterated | Raymond James | Outperform |
| Apr-20-23 | Reiterated | UBS | Buy |
| Apr-20-23 | Reiterated | Wolfe Research | Underperform |
| Mar-29-23 | Initiated | UBS | Buy |
| Oct-26-22 | Initiated | Mizuho | Neutral |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Jul-06-22 | Initiated | Wolfe Research | Underperform |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Jan-27-22 | Reiterated | Credit Suisse | Outperform |
| Jan-27-22 | Reiterated | Morgan Stanley | Overweight |
| Jan-27-22 | Reiterated | Raymond James | Outperform |
| Jan-27-22 | Reiterated | UBS | Buy |
| Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
| Oct-27-21 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Oct-14-21 | Initiated | Redburn | Neutral |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Neutral |
| Jan-28-21 | Upgrade | BTIG Research | Neutral → Buy |
| Sep-11-20 | Initiated | Wolfe Research | Outperform |
| Jun-01-20 | Downgrade | Goldman | Neutral → Sell |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-13-20 | Initiated | Goldman | Neutral |
| Feb-06-20 | Resumed | BTIG Research | Neutral |
| Jan-02-20 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-13-19 | Reiterated | BofA/Merrill | Buy |
| Feb-07-19 | Reiterated | BofA/Merrill | Buy |
| Jan-02-19 | Downgrade | Citigroup | Neutral → Sell |
| Nov-30-18 | Upgrade | Goldman | Neutral → Buy |
| Oct-16-18 | Initiated | Barclays | Overweight |
| Jun-27-18 | Initiated | Bernstein | Outperform |
| Jan-30-18 | Reiterated | Citigroup | Neutral |
| Jan-25-18 | Reiterated | Stifel | Buy |
| Jan-25-18 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jan-03-18 | Initiated | Evercore ISI | Outperform |
| Jan-02-18 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-02-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-19-17 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-19-17 | Reiterated | Stifel | Buy |
View All
Abbott Laboratories Stock (ABT) Latest News
Abbott Laboratories (NYSE: ABT) director receives 432 stock equivalent units as deferred fees - Stock Titan
Abbott Laboratories (ABT) director granted 416 stock equivalent units as board fees - Stock Titan
Abbott (ABT) director receives 363 stock equivalent units as board compensation - Stock Titan
Abbott (ABT) director Kevin Conroy receives 231 stock equivalent units as fees - Stock Titan
Form 4 Abbott Laboratories For: 1 July By Investing.com - Investing.com Canada
Abbott Laboratories (ABT) director receives 347 stock equivalent units as board compensation - Stock Titan
Abbott Laboratories vs. Intuitive Surgical: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Abbott (NYSE: ABT) EVP withholds 269 shares to satisfy tax obligations - Stock Titan
Abbott Laboratories stock outperforms competitors on strong trading day - MarketWatch
Abbott (ABT) Clears A Major Legal Risk As DOJ Ends Criminal Formula Probe - Yahoo Finance
Has Abbott Laboratories (ABT) Fallen Too Far Below Fair Value? - simplywall.st
Baird starts Abbott at Outperform, sees product pipeline driving growth - Yahoo Finance
Baird starts Abbott at Outperform, sees product pipeline driving growth By Investing.com - Investing.com Canada
Abbott Laboratories (ABT) Receives Outperform Rating from Baird with $121 Target - GuruFocus
Abbott Laboratories highlights diversified healthcare portfolio as a long-term driver - AD HOC NEWS
Abbott gains as Baird issues new outperform on growth outlook - MSN
Abbott stock gains as Baird issues new Outperform (ABT:NYSE) - Seeking Alpha
Baird initiates Abbott stock coverage with Outperform rating - Investing.com
Here Are Wednesday’s Best Wall Street Analyst Research Calls: Abbott Laboratories, Circle Internet, Dow, Kratos Defense, Lockheed Martin, Salesforce, ServiceNow,SpaceX, and More - Yahoo Finance
This Abbott Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
Abbott Laboratories stock underperforms Tuesday when compared to competitors - MarketWatch
ABT Stock Quote Price and Forecast - CNN
US criminal probe into Abbott infant-formula plant closed - Global Food Industry News
Trump Admin Stopped Criminal Charges Against Abbott Nutrition for Infant Formula Illnesses - Food Safety Magazine
Abbott Laboratories earnings calendar, shares in focus on the NYSE - AD HOC NEWS
Abbott Laboratories was investigated for poisoning babies. After a $500,000 donation, Trump let them off the hook. - More Perfect Union | Substack
Abbott (ABT) Stock Falls Amid Market Uptick: What Investors Need to Know - Yahoo! Finance Canada
Form 4 Abbott Laboratories For: 29 June By Investing.com - Investing.com Canada
Abbott (ABT) EVP Cushman disposes 560 shares for tax withholding, retains 38,013 - Stock Titan
Abbott Laboratories stock underperforms Monday when compared to competitors - MarketWatch
Coca Cola Stock And 2 Defensive Picks For Steady Dividends - simplywall.st
MDL Sought for Abbott Spinal Cord Stimulator Lawsuits - AboutLawsuits.com
Price to sales forward of Abbott Laboratories Pakistan Limited – PSX:ABOT - TradingView
How Abbott's Largest Segment Is Preparing for the Next Growth Phase - TradingView
Abbott Laboratories dropped from Russell Top 50, shares hold above Tradegate level - AD HOC NEWS
Abbott Laboratories (ABT) Criminal Probe Closed by Justice Depar - GuruFocus
U.S. Justice Department Closes Criminal Probe into Abbott Laboratories - Intellectia AI
DOJ dropped Abbott baby formula criminal probe despite pile of evidence: WSJ (ABT:NYSE) - Seeking Alpha
US DOJ closes criminal probe into Abbott over baby formula plant, WSJ reports - Reuters
Exclusive | The Baby Formula Probe Produced a Pile of Evidence. Then the DOJ Dropped the Case. - WSJ
In a Volatile Market, This Dividend Growth Stock Is Worth Every Penny of $1,000 - The Motley Fool
Enterprise value to revenue forward of Abbott Laboratories – NYSE:ABT - TradingView
Abbott's Dual-Analyte Bet Positions It to Outpace Dexcom in the Expanding CGM Market - Kavout | AI
Abbott Laboratories (ABT) must face a Lawsuit over PediaSure, Statements about Children’s Growth - Insider Monkey
Brain Implants Market Size to Reach USD 18.39 Billion by 2035, Growing at 9.99% CAGR | SNS Insider - GlobeNewswire Inc.
Abbott Laboratories (ABT) Stock After Recent Rebound Is There Still Value Left - Yahoo Finance
Abbott Laboratories' Q2 2026 earnings: What to expect - MSN
Abbott (ABT) Expands In Europe With Instinct CGM And Emerging Market Medicines - simplywall.st
Abbott vs. DexCom: Which CGM Stock Is the Better Option Right Now? - The Globe and Mail
Abbott Laboratories' Q2 2026 Earnings: What to Expect - Barchart.com
Enterprise value to EBIT forward of Abbott Laboratories – NYSE:ABT - TradingView
Abbott Laboratories Stock (ABT) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):